<DOC>
	<DOCNO>NCT02375698</DOCNO>
	<brief_summary>This Phase I , double-blind , randomize , placebo-controlled safety immunogenicity study adult recently successfully treat drug-susceptible pulmonary Tuberculosis ( TB ) . The safety immunogenicity profile escalate dos AERAS-456 HIV-negative subject recently treat drug-susceptible pulmonary TB investigate . The study conduct one sit South Africa .</brief_summary>
	<brief_title>A Phase I Study Safety &amp; Immunogenicity AERAS-456 HIV-Neg . Adults Treated Drug-susceptible Pulmonary TB</brief_title>
	<detailed_description>This study first evaluation AERAS-456 subject complete full course treatment prescribe pulmonary TB . Subjects begin screen study participation complete 4 calendar month TB treatment . Subjects meet inclusion/exclusion criterion randomize within study group 3:1 ratio ( N=18 AERAS-456 ; N=6 placebo ) receive two 0.5 mL intramuscular injection AERAS-456 placebo eight week apart , Study Day 0 Study Day 56 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Is HIVnegative . 2 . Is male female age 18 60 year Study Day 0 . 3 . Has complete write informed consent process . 4 . Has diagnosis confirm pulmonary tuberculosis standard TB treatment . 5 . Is confirmed Mtb negative either 2 GeneXpert test 2 culture sputum sample take 2 different day least 1 week apart , first least 4 calendar month TB treatment second day later 5 calendar month ( window plus 1 week ) treatment . 6 . Agrees complete prescribe course TB treatment ( completion TB treatment occur vaccination Study Day 0 ; subject must complete least 5 calendar month TB treatment Study Day 0 ; TB treatment complete randomization/vaccination time completion TB treatment randomization/vaccination exceed 28 day ) . 7 . For female subject : agree avoid pregnancy screen two month last vaccination . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy 28 day prior administration study vaccine two month last vaccination . Acceptable method avoid pregnancy include sterile sexual partner , sexual abstinence ( engage sexual intercourse ) , hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) . 8 . Agrees stay contact study site full duration study , provide update contact information necessary , current plan move study area duration study . 1 . Evidence new acute illness may compromise safety subject study Study Day 0 . 2 . History TB prior current episode . 3 . TB meningitis form severe TB high risk poor outcome . 4 . Previous medical history may compromise safety subject study , include limit severe impairment pulmonary function tuberculosis infection pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy . 5 . Evidence systemic disease acute chronic illness may interfere evaluation safety vaccine . 6 . History laboratory evidence possible immunodeficiency state . 7 . History allergic disease reaction likely exacerbate component study vaccine . 8 . Received nonBCG TB vaccine previously . 9 . For female subject : Currently pregnant , lactating/nursing , positive urine HCG . 10 . Severe anemia , define hemoglobin le 10 g/dL hematocrit le 30 percent base screen hematology obtain within 7 day randomization Study Day 0 . 11 . History autoimmune disease immunosuppression . 12 . Used immunosuppressive medication within 42 day Study Day 0 ( inhaled topical corticosteroid permit ) . 13 . Received immunoglobulin blood product within 42 day Study Day 0 . 14 . Received investigational drug therapy investigational vaccine within 6 month Study Day 0 , plan participation investigational study study period . 15 . Received licensed vaccine within 28 day Study Day 0 , receipt vaccine immunomodulating agent Study Day 63 . 16 . Is , judgment principal investigator , suitable participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>